Study: Dyax drug lessens symptoms of hereditary angioedema

08/18/2008 | Forbes

Dyax's experimental treatment for hereditary angioedema, DX-88, reduced symptoms of the genetic blood disease in 93.8% of patients who were injected with the drug during a late-stage trial, researchers reported. Dyax is in talks with Dompe Farmaceutici to partner on DX-88 in Europe.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY